|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: GLOBOCAN 2008v2.0: Cancer incidence and
mortality worldwide. IARC CancerBase No. 10 Lyon, France:
International Agency for Research on Cancer; 2010, http://globocan.iorc.fr.
Accessed August 2012
|
|
2
|
Alvi AR, Siddiqui NA and Zafar H: Risk
factors of gallbladder cancer in Karachi-a case-control study.
World J Surg Oncol. 9:1642011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reid KM, Ramos-De la Medina A and Donohue
JH: Diagnosis and surgical management of gallbladder cancer: a
review. J Gastrointest Surg. 11:671–681. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hundal R and Shaffer EA: Gallbladder
cancer: epidemiology and outcome. Clin Epidemiol. 6:99–109.
2014.PubMed/NCBI
|
|
5
|
Jayaraman S and Jarnagin WR: Management of
gallbladder cancer. Gastroenterol Clin North Am. 39:331–342. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kishimoto T: Interleukin-6: discovery of a
pleiotropic cytokine. Arthritis Res Ther. 8(Suppl 2): 22006.
View Article : Google Scholar
|
|
7
|
Qi J, Chen N, Wang J and Siu CH:
Transendothelial migration of melanoma cells involves
N-cadherin-mediated adhesion and activation of the beta-catenin
signaling pathway. Mol Biol Cell. 16:4386–4397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Di GH, Liu Y, Lu Y, Liu J, Wu C and Duan
HF: IL-6 secreted from senescent mesenchymal stem cells promotes
proliferation and migration of breast cancer cells. PLoS One.
9:e1135722014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Soubrane C, Rixe O, Meric JB, Khayat D and
Mouawad R: Pretreatment serum interleukin-6 concentration as a
prognostic factor of overall survival in metastatic malignant
melanoma patients treated with biochemotherapy: a retrospective
study. Melanoma Res. 15:199–204. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ataie-Kachoie P, Pourgholami MH and Morris
DL: Inhibition of the IL-6 signaling pathway: a strategy to combat
chronic inflammatory diseases and cancer. Cytokine Growth Factor
Rev. 24:163–173. 2013. View Article : Google Scholar
|
|
11
|
Sullivan NJ, Sasser AK, Axel AE, et al:
Interleukin-6 induces an epithelial-mesenchymal transition
phenotype in human breast cancer cells. Oncogene. 28:2940–2947.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Na YR, Lee JS, Lee SJ and Seok SH:
Interleukin-6-induced Twist and N-cadherin enhance melanoma cell
metastasis. Melanoma Res. 23:434–443. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thiery JP: Epithelial-mesencymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu AN, Zhu ZH, Chang SJ and Hang XS:
Twist expression associated with the epithelial-mesenchymal
transition in gastric cancer. Mol Cell Biochem. 367:195–203. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qin Y, Zhang S, Gong W, Li J, Jia J and
Quan Z: Adenovirus-mediated gene transfer of tissue factor pathway
inhibitor-2 inhibits gallbladder carcinoma growth in vitro and in
vivo. Cancer Sci. 103:723–730. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Diehl S, Anguita J, Hoffmeyer A, et al:
Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1.
Immunity. 13:805–815. 2000. View Article : Google Scholar
|
|
17
|
Luo F, Xu Y, Ling M, et al: Arsenite
evokes IL-6 secretion, autocrine regulation of STAT3 signaling and
miR-21 expression, processes involved in the EMT and malignant
transformation of human bronchial epithelial cells. Toxicol Appl
Pharmacol. 273:27–34. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Y, Qu Y, Zhang XL, et al: Autocrine
production of interleukin-6 confers ovarian cancer cells resistance
to tamoxifen via ER isoforms and SRC-1. Mol Cell Endocrinol.
2013.
|
|
19
|
Yeh KY, Li YY, Hsieh LL, et al: Analysis
of the effect of serum interleukin-6 (IL-6) and soluble IL-6
receptor levels on survival of patients with colorectal cancer. Jpn
J Clin Oncol. 40:580–587. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Duffy SA, Taylor JM, Terrell JE, et al:
Interleukin-6 predicts recurrence and survival among head and neck
cancer patients. Cancer. 113:750–757. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Suh SY, Choi YS, Yeom CH, et al:
Interleukin-6 but not tumour necrosis factor-alpha predicts
survival in patients with advanced cancer. Support Care Cancer.
21:3071–3077. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang CH, Hsiao CF, Yeh YM, et al:
Circulating interleukin-6 level is a prognostic marker for survival
in advanced nonsmall cell lung cancer patients treated with
chemotherapy. Int J Cancer. 132:1977–1985. 2013. View Article : Google Scholar
|
|
23
|
Yu H, Kortylewski M and Pardoll D:
Crosstalk between cancer and immune cells: role of STAT3 in the
tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar
|
|
24
|
Ho PL, Lay EJ, Jian W, Parra D and Chan
KS: Stat3 activation in urothelial stem cells leads to direct
progression to invasive bladder cancer. Cancer Res. 72:3135–3142.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rathinavelu A, Narasimhan M and Muthumani
P: A novel regulation of VEGF expression by HIF-1α and STAT3 in
HDM2 transfected prostate cancer cells. J Cell Mol Med.
16:1750–1757. 2012. View Article : Google Scholar
|
|
26
|
Yadav A, Kumar B, Datta J, Teknos TN and
Kumar P: IL-6 promotes head and neck tumor metastasis by inducing
epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling
pathway. Mol Cancer Res. 9:1658–1667. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
de Freitas Silva BS, Yamamoto-Silva FP,
Pontes HA and Pinto Júnior DS: E-cadherin downregulation and Twist
overexpression since early stages of oral carcinogenesis. J Oral
Pathol Med. 43:125–31. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yuen HF, Chua CW, Chan YP, Wong YC, Wang X
and Chan KW: Significance of TWIST and E-cadherin expression in the
metastatic progression of prostatic cancer. Histopathology.
50:648–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shibata K, Kajiyama H, Ino K, et al: Twist
expression in patients with cervical cancer is associated with poor
disease outcome. Ann Oncol. 19:81–85. 2008. View Article : Google Scholar
|
|
30
|
Zhao Z, Ge J, Sun Y, et al: Is E-cadherin
immunoexpression a prognostic factor for head and neck squamous
cell carcinoma (HNSCC)? A systematic review and meta-analysis. Oral
Oncol. 48:761–767. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bačić B, Haller H, Mrklić I, Košta V,
Čarić A and Tomić S: Prognostic role of E-cadherin in patients with
advanced serous ovarian cancer. Arch Gynecol Obstet. 287:1219–1224.
2013. View Article : Google Scholar
|
|
32
|
Aamodt R, Bondi J, Andersen SN, Bakka A,
Bukholm G and Bukholm IR: The prognostic impact of protein
expression of E-cadherin-catenin complexes differs between rectal
and colon carcinoma. Gastroenterol Res Pract. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shinriki S, Jono H, Ota K, et al:
Humanized anti-interleukin-6 receptor antibody suppresses tumor
angiogenesis and in vivo growth of human oral squamous cell
carcinoma. Clin Cancer Res. 15:5426–5434. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guo Y, Xu F, Lu T, Duan Z and Zhang Z:
Interleukin-6 signaling pathway in targeted therapy for cancer.
Cancer Treat Rev. 38:904–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
